Stockscreener 앱 받기
37.61
1.65%
0.61
시장 영업 전:
39.49
1.88
+5.00%
Korro Bio Inc 주식(KRRO)의 최신 뉴스
Korro Bio (NASDAQ:KRRO) Doses First Participants in REWRITE Phase 1/2a Clinical Study – Pipeline Update ProvidedOn January 13, 2025, Korro Bio, Inc. issued a press release stating that it had initiated dosing the first participants in its REWRITE Pha - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Update - MarketBeat
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update - The Manila Times
Korro Bio Launches First Clinical Trial for AATD Treatment KRRO-110, Marks Clinical Stage Milestone - StockTitan
Korro Bio (NASDAQ:KRRO) Research Coverage Started at Oppenheimer - Defense World
Korro Bio (NASDAQ:KRRO) Now Covered by Analysts at Oppenheimer - MarketBeat
Korro Bio CEO to Present RNA Editing Breakthroughs at JP Morgan Healthcare Conference - StockTitan
Geode Capital Management LLC Sells 2,161 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Buy” from Analysts - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Stock Position Increased by State Street Corp - MarketBeat
State Street Corp Acquires 18,877 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio: Still Too Long To Go… Just Keep Watching For Now (Rating Upgrade) (NASDAQ:KRRO) - Seeking Alpha
Wellington Management Group LLP Invests $436,000 in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Frequency Therapeutics : The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Frequency Therapeutics, Inc. (FREQ) Investors - Marketscreener.com
BNP Paribas Financial Markets Purchases 4,470 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical catalyst - Investing.com Nigeria
Fmr LLC Has $19.37 Million Holdings in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Why Korro Bio (KRRO) Should Be on Your Investment Radar - Nasdaq
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
100-employee biotech opens new Kendall Square HQ - The Business Journals
Verition Fund Management LLC Has $3.12 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News
Korro Bio, Inc. (NASDAQ:KRRO) Short Interest Down 6.5% in November - Defense World
Quest Partners LLC Has $59,000 Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Eventide Asset Management LLC Sells 137,989 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully - Simply Wall St
Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com
HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat
Korro Bio (NASDAQ:KRRO) Receives Buy Rating from HC Wainwright - MarketBeat
Korro secures approvals in Australia to commence AATD trial of KRRO-110 - Yahoo Finance
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio CEO to Present at Major Healthcare Conferences in December | KRRO Stock News - StockTitan
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Korro Bio Gains Approval for Phase 1/2a AATD Treatment Trial, Shows Strong Preclinical Data | KRRO Stock News - StockTitan
Jones Trading bullish on Korro Bio stock amid RNA editing and AATD prospects - Investing.com
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Korro Bio FY2024 EPS Forecast Increased by HC Wainwright - MarketBeat
William Blair Has Positive View of Korro Bio FY2024 Earnings - MarketBeat
Jones Trading Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - MSN
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Eventide Asset Management's Strategic Reduction in Korro Bio Inc Holdings - GuruFocus.com
Deep Track Capital, LP's Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro to Present at the Jefferies London Healthcare Conference - The Manila Times
Korro Bio to Present RNA-Editing Breakthroughs at Jefferies London Healthcare Conference | KRRO Stock News - StockTitan
Korro Bio’s Progress and Financial Updates - TipRanks
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
William Blair Reiterates "Outperform" Rating for Korro Bio (NASDAQ:KRRO) - MarketBeat
4.81%
자본화:
|
볼륨(24시간):